Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer

Ketan Patel, Ravi Doddapaneni, Nusrat Chowdhury, Cedar H.A. Boakye, Gautam Behl, Mandip Singh

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)

Abstract

Aim: Therapeutic efficacy of anticancer nanomedicine is compromised by tumor stromal barriers. The present study deals with the development of docetaxel loaded PEGylated liposomes (DTXPL) and to investigate the effect of tumor stroma disrupting agent, telmisartan, on anticancer efficacy of DTXPL. Methods: DTXPL was prepared using proprietary modified hydration method. Effect of oral telmisartan treatment on tumor uptake of coumarin-6 liposomes and anticancer efficacy of DTXPL was evaluated in orthotopic xenograft lung tumor bearing mice. Results: DTXPL (105.7 ± 3.8 nm) showed very high physical stability, negligible hemolysis, 428% enhancement in bioavailability with significantly higher intratumoral uptake. Marked reduction in collagen-I, MMP2/9 and lung tumor weight were observed in DTXPL+telmisartan group. Conclusion: Combination of DTXPL with telmisartan could significantly enhance clinical outcome in lung cancer.

Original languageEnglish
Pages (from-to)1377-1392
Number of pages16
JournalNanomedicine
Volume11
Issue number11
DOIs
Publication statusPublished - Jun 2016
Externally publishedYes

Keywords

  • cancer nanomedicine
  • docetaxel
  • orthotopic lung cancer
  • pegylated liposome
  • solid tumor targeting
  • tumor fibrosis
  • tumor stroma

Fingerprint

Dive into the research topics of 'Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer'. Together they form a unique fingerprint.

Cite this